Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Global X Data Center & Digital Infra ETF (DTCR) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance

Global X Data Center & Digital Infra ETFTrade
Regeneron Pharmaceuticals IncTrade

Price performance (Past 24H)

Key statistics

Global X Data Center & Digital Infra ETF vs Regeneron Pharmaceuticals Inc — how do they compare? Global X Data Center & Digital Infra ETF trades at $27.5 (market cap $2.08B), while Regeneron Pharmaceuticals Inc trades at $737.72 (market cap $76.40B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 36.7× Global X Data Center & Digital Infra ETF's market cap, and Regeneron Pharmaceuticals Inc pays a 0.51% dividend while Global X Data Center & Digital Infra ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Global X Data Center & Digital Infra ETF for 15 Days and Regeneron Pharmaceuticals Inc for 107 Days on average.

DTCRREGN
Market Cap
$2.08B$76.40B
Volume
764,577626,381
Sector
Sector/ThematicHealth
52-Week High
$32.46$852.03
52-Week Low
$19.73$557.73
Typical Hold Time
15 Days107 Days
Enterprise Value
—$71.12B
Dividend Yield
—0.51%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Global X Data Center & Digital Infra ETF

No Aura AI signal available yet.

Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals (REGN) trades at $739.57, up 0.12% on the day, with a bearish technical signal but strong fundamental performance. Recent earnings have consistently beaten estimates, and the company maintains robust profitability with a net income margin of 27.86%. A major $8 billion expansion of the immunology alliance with Sanofi, announced October 1, 2026, provides significant future revenue potential and strategic momentum.

The outlook is positive, supported by strong earnings, a lucrative partnership, and a consensus analyst price target of $846. Key risks include competitive pressures in key drug markets and reliance on successful clinical trial outcomes. The stock presents a compelling opportunity for growth investors, though volatility may persist near-term.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

DTCR
68% Buy32% Sell
Avg holding period · 15 Days
REGN
98% Buy2% Sell
Avg holding period · 107 Days

Top news

Latest headlines on both assets

About Global X Data Center & Digital Infra ETF

Global X Data Center & Digital Infrastructure ETF seeks exposure to companies involved in data centers and digital infrastructure. Its holdings span areas such as digital infrastructure, networking, and related real estate.

Read more on DTCR →

About Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases

Read more on REGN →